|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
1998-7-13
|
|
pubmed:abstractText |
The potent mitogenic activity of insulin-like growth factor I (IGF-I) on breast epithelium is inhibited by retinoic acid in oestrogen receptor-positive (ER+) breast cancer cell lines. We studied and compared the effects of N-(4-hydroxyphenyl)-retinamide (4-HPR) in terms of growth inhibition and modulation of the IGF-I system in ER+ (MCF-7) and oestrogen receptor-negative (ER-) (MDA-MB231) breast cancer cell lines. Treatment with 1-10 microM 4-HPR for up to 96 h induced a dose- and time-dependent inhibition of proliferation in both breast cancer cell lines. Induction of apoptosis was much more evident in MCF-7 than in MDA-MB231 cells (30-40% compared with 0-5% respectively at 5 microM for 48 h). Exogenous human recombinant IGF-I (hr-IGF-I)-stimulated cell proliferation was abolished by 1 microM 4-HPR in MCF-7 cells. Immunoreactive IGF-I-like protein concentration in conditioned medium was reduced by 38% in MCF-7 and by 90% in MDA-MB231 cell lines following treatment for 48 h with 5 microM 4-HPR. Western ligand blot analysis showed a reduction of IGF-binding protein 4 (BP4) and BP5 by 67% and 87%, respectively, in MCF-7, whereas IGF-BP4 and -BP1 were reduced by approximately 20% in MDA-MB231 cells. Exposure to 5 microM 4-HPR for 48 h inhibited [125I]IGF-I binding and Scatchard analysis revealed a decrease of more than 50% in maximum binding capacity (Bmax) and a reduced receptor number/cell in both cancer cell lines. Steady-state type I IGF-receptor mRNA levels were reduced by approximately 30% in both tumour cell lines. We conclude that 4-HPR induces a significant down-regulation of the IGF-I system in both ER+ (MCF-7) and ER- (MDA-MB231) breast cancer cell lines. These findings suggest that, in our model, interference with the ER signalling pathway is not the only mechanism of breast cancer growth inhibition by 4-HPR.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-1281161,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-1313739,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-1333659,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-1333943,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-1373590,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-1379645,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-1382963,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-1384805,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-1399128,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-1569455,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-1648728,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-1701124,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-1713084,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-1861990,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-2084471,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-2174732,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-2557327,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-2747657,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-2932587,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-3180080,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-3283939,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-3731113,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-421218,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-427741,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-518835,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-7188772,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-7473809,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-7509779,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-7525978,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-7543456,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-7585542,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-7586155,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-7588759,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-7593132,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-7619109,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-7684042,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-7690042,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-7811993,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-7812953,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-7850799,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-7987855,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-8125161,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-8386111,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-8402658,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-8557625,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-8603400,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649125-8798408
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
77
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2138-47
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:9649125-Antineoplastic Agents,
pubmed-meshheading:9649125-Breast Neoplasms,
pubmed-meshheading:9649125-Cell Division,
pubmed-meshheading:9649125-DNA, Neoplasm,
pubmed-meshheading:9649125-Drug Interactions,
pubmed-meshheading:9649125-Fenretinide,
pubmed-meshheading:9649125-Humans,
pubmed-meshheading:9649125-Insulin-Like Growth Factor I,
pubmed-meshheading:9649125-Receptors, Estrogen,
pubmed-meshheading:9649125-Receptors, Somatomedin,
pubmed-meshheading:9649125-Tumor Cells, Cultured
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.
|
|
pubmed:affiliation |
Department of Preclinical Oncology, National Institute for Cancer Research and Advanced Biotechnology Center, Genoa, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
